Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 601

Similar articles for PubMed (Select 18308388)

1.

Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.

Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC.

Leuk Res. 2008 Sep;32(9):1476-9. doi: 10.1016/j.leukres.2008.01.012. Epub 2008 Mar 4.

PMID:
18308388
2.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7. Epub 2003 Feb 6.

3.

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.

Am J Clin Pathol. 2003 Jun;119(6):833-41.

4.
5.

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

Kolb EA, Pan Q, Ladanyi M, Steinherz PG.

Cancer. 2003 Dec 15;98(12):2643-50. Review.

6.

Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.

Pompetti F, Spadano A, Sau A, Mennucci A, Russo R, Catinella V, Franchi PG, Calabrese G, Palka G, Fioritoni G, Iacone A.

Leuk Res. 2007 Apr;31(4):563-7. Epub 2006 Aug 17.

PMID:
16916543
7.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

8.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
9.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

10.

Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.

Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.

Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5.

PMID:
17452251
11.

Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.

Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, Reiffers J, Praloran V, Mahon FX.

Haematologica. 2006 Feb;91(2):162-8.

12.

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW.

Blood. 2003 Mar 1;101(5):1941-9. Epub 2002 Oct 31.

13.
14.

[The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].

Miyanishi S, Umeki K, Hayashi T, Fukutsuka K, Okumura A, Kishimori C.

Rinsho Byori. 2003 Oct;51(10):1023-9. Japanese.

PMID:
14653203
15.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.

Haematologica. 2004 Jan;89(1):49-57.

16.

Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.

Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M, Tatsumi Y, Maeda Y, Kanamaru A.

Int J Hematol. 2005 May;81(4):307-9.

PMID:
15914360
17.

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ.

Blood. 2006 Jun 1;107(11):4250-6. Epub 2006 Feb 7.

18.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.

Kim YJ, Kim DW, Lee S, Min CK, Goh HG, Kim SH, Lee JY, Kim YL, Kim HJ, Kim HJ, Lee JW, Kim TG, Min WS, Kim CC.

Biol Blood Marrow Transplant. 2004 Oct;10(10):718-25.

19.

Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.

Kroschinsky F, Friedrich K, Hanel M, Mohr B, Langer T, Meinhardt M, Thiede C, Bornhauser M, Baretton G, Ehninger G.

Ann Hematol. 2003 Jan;82(1):47-52. Epub 2002 Nov 29.

PMID:
12574966
20.

Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.

Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S.

Cancer Genet Cytogenet. 2001 Dec;131(2):125-34.

PMID:
11750052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk